Bearss D - Search Results

1

New drugs for patients with pancreatic cancer.

Von Hoff DD, Bearss D. Von Hoff DD, et al. Among authors: bearss d. Curr Opin Oncol. 2002 Nov;14(6):621-7. doi: 10.1097/00001622-200211000-00006. Curr Opin Oncol. 2002. PMID: 12409652 Review.

2

Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.

Vankayalapati H, Bearss DJ, Saldanha JW, Muñoz RM, Rojanala S, Von Hoff DD, Mahadevan D. Vankayalapati H, et al. Among authors: bearss dj. Mol Cancer Ther. 2003 Mar;2(3):283-94. Mol Cancer Ther. 2003. PMID: 12657723

3

Targeting Aurora-2 kinase in cancer.

Warner SL, Bearss DJ, Han H, Von Hoff DD. Warner SL, et al. Among authors: bearss dj. Mol Cancer Ther. 2003 Jun;2(6):589-95. Mol Cancer Ther. 2003. PMID: 12813139 Review.

4

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ. Rojanala S, et al. Among authors: bearss dj. Mol Cancer Ther. 2004 Apr;3(4):451-7. Mol Cancer Ther. 2004. PMID: 15078988

5

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.

Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD. Gray PJ Jr, et al. Among authors: bearss dj. Mol Cancer Ther. 2004 May;3(5):641-6. Mol Cancer Ther. 2004. PMID: 15141022

6

Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Warner SL, Muñoz RM, Bearss DJ, Grippo P, Han H, Von Hoff DD. Warner SL, et al. Among authors: bearss dj. Pancreas. 2008 Oct;37(3):e39-44. doi: 10.1097/MPA.0b013e318176b9ae. Pancreas. 2008. PMID: 18815537 Free PMC article.

7

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Han H, et al. Among authors: bearss dj. Cancer Res. 2002 May 15;62(10):2890-6. Cancer Res. 2002. PMID: 12019169

8

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ. Grand CL, et al. Among authors: bearss dj. Mol Cancer Ther. 2002 Jun;1(8):565-73. Mol Cancer Ther. 2002. PMID: 12479216

9

Telomere maintenance mechanisms as a target for drug development.

Bearss DJ, Hurley LH, Von Hoff DD. Bearss DJ, et al. Oncogene. 2000 Dec 27;19(56):6632-41. doi: 10.1038/sj.onc.1204092. Oncogene. 2000. PMID: 11426649 Review.

10

Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.

Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH. Warner SL, et al. Among authors: bearss dj. Mol Cancer Ther. 2006 Jul;5(7):1764-73. doi: 10.1158/1535-7163.MCT-05-0524. Mol Cancer Ther. 2006. PMID: 16891462

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters